vs
优尼威（CLMB）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是优尼威的1.1倍（$197.9M vs $182.4M），REPLIGEN CORP净利率更高（6.7% vs 1.8%，领先4.9%），优尼威同比增速更快（32.1% vs 13.6%），过去两年优尼威的营收复合增速更高（40.7% vs 14.4%）
优尼威解决方案是一家全球化学品与原料分销商，同时可为客户提供各类增值服务，在行业内拥有广泛的全球布局与专业服务能力。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
CLMB vs RGEN — 直观对比
营收规模更大
RGEN
是对方的1.1倍
$182.4M
营收增速更快
CLMB
高出18.5%
13.6%
净利率更高
RGEN
高出4.9%
1.8%
两年增速更快
CLMB
近两年复合增速
14.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $182.4M | $197.9M |
| 净利润 | $3.3M | $13.3M |
| 毛利率 | 14.5% | 52.5% |
| 营业利润率 | 2.1% | 9.0% |
| 净利率 | 1.8% | 6.7% |
| 营收同比 | 32.1% | 13.6% |
| 净利润同比 | -9.5% | 143.9% |
| 每股收益（稀释后） | $0.18 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLMBRGEN
| Q1 26 | $182.4M | — | ||
| Q4 25 | $193.8M | $197.9M | ||
| Q3 25 | $161.3M | $188.8M | ||
| Q2 25 | $159.3M | $182.4M | ||
| Q1 25 | $138.0M | $169.2M | ||
| Q4 24 | $161.8M | $174.1M | ||
| Q3 24 | $119.3M | $154.9M | ||
| Q2 24 | $92.1M | $154.1M |
净利润CLMBRGEN
| Q1 26 | $3.3M | — | ||
| Q4 25 | $7.0M | $13.3M | ||
| Q3 25 | $4.7M | $14.9M | ||
| Q2 25 | $6.0M | $14.9M | ||
| Q1 25 | $3.7M | $5.8M | ||
| Q4 24 | $7.0M | $-30.3M | ||
| Q3 24 | $5.5M | $-654.0K | ||
| Q2 24 | $3.4M | $3.3M |
毛利率CLMBRGEN
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | 52.5% | ||
| Q3 25 | 15.9% | 53.2% | ||
| Q2 25 | 16.5% | 50.0% | ||
| Q1 25 | 16.9% | 53.6% | ||
| Q4 24 | 19.3% | 26.1% | ||
| Q3 24 | 20.3% | 50.0% | ||
| Q2 24 | 20.2% | 49.8% |
营业利润率CLMBRGEN
| Q1 26 | 2.1% | — | ||
| Q4 25 | 4.9% | 9.0% | ||
| Q3 25 | 4.3% | 8.9% | ||
| Q2 25 | 5.0% | 7.6% | ||
| Q1 25 | 3.5% | 3.9% | ||
| Q4 24 | 7.2% | -17.7% | ||
| Q3 24 | 7.1% | -5.1% | ||
| Q2 24 | 4.6% | 1.0% |
净利率CLMBRGEN
| Q1 26 | 1.8% | — | ||
| Q4 25 | 3.6% | 6.7% | ||
| Q3 25 | 2.9% | 7.9% | ||
| Q2 25 | 3.7% | 8.2% | ||
| Q1 25 | 2.7% | 3.4% | ||
| Q4 24 | 4.3% | -17.4% | ||
| Q3 24 | 4.6% | -0.4% | ||
| Q2 24 | 3.7% | 2.2% |
每股收益（稀释后）CLMBRGEN
| Q1 26 | $0.18 | — | ||
| Q4 25 | $1.51 | $0.24 | ||
| Q3 25 | $1.02 | $0.26 | ||
| Q2 25 | $1.30 | $0.26 | ||
| Q1 25 | $0.81 | $0.10 | ||
| Q4 24 | $1.52 | $-0.55 | ||
| Q3 24 | $1.19 | $-0.01 | ||
| Q2 24 | $0.75 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.8M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $118.4M | $2.1B |
| 总资产 | $458.8M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资CLMBRGEN
| Q1 26 | $41.8M | — | ||
| Q4 25 | $36.6M | $767.6M | ||
| Q3 25 | $49.8M | $748.7M | ||
| Q2 25 | $28.6M | $708.9M | ||
| Q1 25 | $32.5M | $697.2M | ||
| Q4 24 | $29.8M | $757.4M | ||
| Q3 24 | $22.1M | $784.0M | ||
| Q2 24 | $48.4M | $809.1M |
总债务CLMBRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CLMBRGEN
| Q1 26 | $118.4M | — | ||
| Q4 25 | $116.6M | $2.1B | ||
| Q3 25 | $109.3M | $2.1B | ||
| Q2 25 | $105.2M | $2.1B | ||
| Q1 25 | $95.6M | $2.0B | ||
| Q4 24 | $90.6M | $2.0B | ||
| Q3 24 | $87.7M | $2.0B | ||
| Q2 24 | $79.8M | $2.0B |
总资产CLMBRGEN
| Q1 26 | $458.8M | — | ||
| Q4 25 | $460.2M | $2.9B | ||
| Q3 25 | $376.1M | $2.9B | ||
| Q2 25 | $420.7M | $2.9B | ||
| Q1 25 | $370.1M | $2.9B | ||
| Q4 24 | $469.2M | $2.8B | ||
| Q3 24 | $371.9M | $2.8B | ||
| Q2 24 | $302.8M | $2.9B |
负债/权益比CLMBRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $25.7M |
| 自由现金流经营现金流 - 资本支出 | — | $17.6M |
| 自由现金流率自由现金流/营收 | — | 8.9% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流CLMBRGEN
| Q1 26 | — | — | ||
| Q4 25 | $-11.9M | $25.7M | ||
| Q3 25 | $22.2M | $48.1M | ||
| Q2 25 | $-2.2M | $28.6M | ||
| Q1 25 | $8.5M | $15.0M | ||
| Q4 24 | $16.0M | $39.2M | ||
| Q3 24 | $-3.6M | $49.3M | ||
| Q2 24 | $7.3M | $42.2M |
自由现金流CLMBRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $43.4M | ||
| Q2 25 | — | $21.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $33.6M | ||
| Q3 24 | — | $42.3M | ||
| Q2 24 | — | $37.4M |
自由现金流率CLMBRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 8.9% | ||
| Q3 25 | — | 23.0% | ||
| Q2 25 | — | 11.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 27.3% | ||
| Q2 24 | — | 24.3% |
资本支出强度CLMBRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 3.1% |
现金转化率CLMBRGEN
| Q1 26 | — | — | ||
| Q4 25 | -1.70× | 1.93× | ||
| Q3 25 | 4.73× | 3.23× | ||
| Q2 25 | -0.37× | 1.92× | ||
| Q1 25 | 2.30× | 2.57× | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | -0.66× | — | ||
| Q2 24 | 2.13× | 12.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
